COVID-19 Vaccine Tracker

About Trial Phases

Last Updated 11 June 2021.

17 Vaccines Approved by at Least One Country

• Anhui Zhifei Longcom
  RBD-Dimer

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 2 countries

  6 trials in 5 countries

  Protein Subunit

• Bharat Biotech
  Covaxin

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 9 countries

  5 trials in 1 country

  Inactivated

• CanSino
  Ad5-nCoV

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 5 countries

  8 trials in 6 countries

  Non Replicating Viral Vector

• Chumakov Center
  KoviVac

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 1 country

  2 trials in 1 country

  Inactivated

• FBRI
  EpiVacCorona

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 2 countries

  3 trials in 1 country

  Protein Subunit

• Gamaleya
  Sputnik V

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 68 countries

  19 trials in 6 countries

  Non Replicating Viral Vector

• Janssen (Johnson & Johnson)
  Ad26.COV2.S

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 44 countries

  11 trials in 17 countries

  Non Replicating Viral Vector

• Kazakhstan RIBSP
  QazVac

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 1 country

  3 trials in 1 country

  Inactivated

• Minhai Biotechnology Co
  SARS-CoV-2 Vaccine (Vero Cells)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 1 country

  3 trials in 1 country

  Inactivated

• Moderna
  mRNA-1273

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 49 countries

  21 trials in 4 countries

  RNA

• Oxford/AstraZeneca
  AZD1222

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 102 countries

  32 trials in 19 countries

  Non Replicating Viral Vector

• Pfizer/BioNTech
  BNT162b2

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 85 countries

  26 trials in 15 countries

  RNA

• Serum Institute of India
  Covishield

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 40 countries

  2 trials in 1 country

  Non Replicating Viral Vector

• Sinopharm (Beijing)
  BBIBP-CorV

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 47 countries

  6 trials in 7 countries

  Inactivated

• Sinopharm (Wuhan)
  Inactivated (Vero Cells)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 1 country

  8 trials in 7 countries

  Inactivated

• Sinovac
  CoronaVac

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 26 countries

  15 trials in 7 countries

  Inactivated

• Takeda
  TAK-919

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 1 country

  2 trials in 1 country

  RNA

35 Vaccines in Phase 3 Clinical Trials

• Instituto Finlay de Vacunas Cuba
  FINLAY-FR-2

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  3 trials in 1 country

  Protein Subunit

• West China Hospital
  Recombinant (Sf9 cell)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  5 trials in 1 country

  Protein Subunit

• Serum Institute of India
  COVOVAX

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  2 trials in 1 country

  Protein Subunit

• Center for Genetic Engineering and Biotechnology (CIGB)
  CIGB-66

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  5 trials in 1 country

  Protein Subunit

• Sanofi/GSK
  Recombinant Protein

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  5 trials in 2 countries

  Protein Subunit

• Clover
  SCB-2019

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  5 trials in 10 countries

  Protein Subunit

• COVAXX
  UB-612

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  4 trials in 1 country

  Protein Subunit

• Novavax
  NVX-CoV2373

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  8 trials in 7 countries

  Protein Subunit

• FBRI
  EpiVacCorona

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 2 countries

  3 trials in 1 country

  Protein Subunit

• Anhui Zhifei Longcom
  RBD-Dimer

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 2 countries

  6 trials in 5 countries

  Protein Subunit

• Instituto Finlay de Vacunas Cuba
  FINLAY-FR-1A

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  3 trials in 1 country

  Protein Subunit

• Medicago
  Plant-based VLP

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  3 trials in 2 countries

  VLP

• AnGes
  AG0302-COVID19

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  4 trials in 1 country

  DNA

• Zydus Cadila
  ZyCoV-D

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  5 trials in 1 country

  DNA

• Inovio
  INO-4800

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  6 trials in 3 countries

  DNA

• Moderna
  mRNA-1273

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 49 countries

  21 trials in 4 countries

  RNA

• Curevac
  CVnCoV

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  11 trials in 12 countries

  RNA

• Pfizer/BioNTech
  BNT162b1

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  5 trials in 3 countries

  RNA

• Pfizer/BioNTech
  BNT162b2

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 85 countries

  26 trials in 15 countries

  RNA

• Walvax
  mRNA

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  4 trials in 1 country

  RNA

• Janssen (Johnson & Johnson)
  Ad26.COV2.S

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 44 countries

  11 trials in 17 countries

  Non Replicating Viral Vector

• Gamaleya
  Sputnik V

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 68 countries

  19 trials in 6 countries

  Non Replicating Viral Vector

• Oxford/AstraZeneca
  AZD1222

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 102 countries

  32 trials in 19 countries

  Non Replicating Viral Vector

• ReiThera
  GRAd-COV2

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  5 trials in 12 countries

  Non Replicating Viral Vector

• Serum Institute of India
  Covishield

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 40 countries

  2 trials in 1 country

  Non Replicating Viral Vector

• CanSino
  Ad5-nCoV

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 5 countries

  8 trials in 6 countries

  Non Replicating Viral Vector

• Sinovac
  CoronaVac

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 26 countries

  15 trials in 7 countries

  Inactivated

• Bharat Biotech
  Covaxin

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 9 countries

  5 trials in 1 country

  Inactivated

• Valneva
  VLA2001

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  4 trials in 1 country

  Inactivated

• Chinese Academy of Medical Sciences
  Inactivated (Vero Cells)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  5 trials in 3 countries

  Inactivated

• Sinopharm (Wuhan)
  Inactivated (Vero Cells)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 1 country

  8 trials in 7 countries

  Inactivated

• Sinopharm (Beijing)
  BBIBP-CorV

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 47 countries

  6 trials in 7 countries

  Inactivated

• Shifa Pharmed Industrial Co
  COVID-19 Inactivated Vaccine

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 3 trials.

  4 trials in 1 country

  Inactivated

• Kazakhstan RIBSP
  QazVac

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 1 country

  3 trials in 1 country

  Inactivated

• Minhai Biotechnology Co
  SARS-CoV-2 Vaccine (Vero Cells)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 1 country

  3 trials in 1 country

  Inactivated

48 Vaccines in Phase 2 Clinical Trials

• SK Bioscience Co Ltd
  GBP510

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  4 trials in 1 country

  Protein Subunit

• EuBiologics Co Ltd
  EuCorVac-19

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• Razi Vaccine and Serum Research Institute
  Razi Cov Pars

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• National Vaccine and Serum Institute
  Recombinant SARS-CoV-2 Vaccine (CHO Cell)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• Nanogen
  Nanocovax

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• Medigen
  MVC-COV1901

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  3 trials in 2 countries

  Protein Subunit

• Livzon Mabpharm Inc
  V-01

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• Kentucky Bioprocessing
  KBP-201

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• University Medical Center Groningen
  AKS-452

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• Instituto Finlay de Vacunas Cuba
  FINLAY-FR-1

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  3 trials in 1 country

  Protein Subunit

• Takeda
  TAK-019

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• Shionogi
  S-268019

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• University of Saskatchewan
  COVAC-2

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• Center for Genetic Engineering and Biotechnology (CIGB)
  CIGB-669

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• Biological E Limited
  BECOV2A

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• Biological E Limited
  BECOV2B

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  0 trials in 1 country

  Protein Subunit

• Biological E Limited
  BECOV2C

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  0 trials in 1 country

  Protein Subunit

• Vaxine
  COVAX-19

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 2 countries

  Protein Subunit

• Biological E Limited
  BECOV2D

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Protein Subunit

• SpyBiotech
  RBD SARS-CoV-2 HBsAg VLP

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  VLP

• VBI Vaccines Inc
  VBI-2902a

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  VLP

• Entos Pharmaceuticals Inc
  Covigenix VAX-001

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  DNA

• AnGes
  AG0301-COVID19

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  DNA

• Takis
  COVID-eVax

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  DNA

• Genexine
  GX-19

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  4 trials in 1 country

  DNA

• GeneOne Life Science Inc
  GLS-5310

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  DNA

• Chulalongkorn University
  ChulaCov19

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  RNA

• Elixirgen Therapeutics Inc
  EXG-5003

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  RNA

• Daiichi Sankyo Co Ltd
  DS-5670a

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  RNA

• Gennova Biopharmaceuticals Limited
  HGCO19

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  RNA

• Pfizer/BioNTech
  BNT162a1

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  RNA

• Pfizer/BioNTech
  BNT162b3

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  RNA

• Pfizer/BioNTech
  BNT162c2

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  RNA

• Arcturus Therapeutics Inc
  LUNAR-COV19/ARCT-021

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  4 trials in 2 countries

  RNA

• Sanofi Pasteur
  MRT5500

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  RNA

• Takeda
  TAK-919

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 1 country

  2 trials in 1 country

  RNA

• Institute of Vaccines and Medical Biologicals
  COVIVAC

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Non Replicating Viral Vector

• Shenzhen Geno-Immune Medical Institute
  LV-SMENP

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Non Replicating Viral Vector

• Universitätsklinikum Hamburg-Eppendorf
  MVA-SARS-2-ST

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Non Replicating Viral Vector

• ImmunityBio Inc
  hAd5-Covid-19

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  7 trials in 2 countries

  Non Replicating Viral Vector

• Aivita Biomedical Inc
  AV-COVID-19

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  3 trials in 2 countries

  Replicating Viral Vector

• Wantai
  DelNS1-2019-nCoV-RBD-OPT

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Replicating Viral Vector

• Mahidol University
  NDV-HXP-S

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Replicating Viral Vector

• Israel Institute for Biological Research (IIBR)
  IIBR-100

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Replicating Viral Vector

• Cellid Co
  AdCLD-CoV19

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Replicating Viral Vector

• Health Institutes of Turkey
  ERUCOV-VAC

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Inactivated

• Chumakov Center
  KoviVac

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine is approved.

  Approved in 1 country

  2 trials in 1 country

  Inactivated

• KM Biologics Co Ltd
  KD-414

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 1 country

  Inactivated

35 Vaccines in Phase 1 Clinical Trials

• Adimmune Corporation
  AdimrSC-2f

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Protein Subunit

• Jiangsu Rec-Biotechnology Co Ltd
  ReCOV

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Protein Subunit

• US Army Medical Research and Development Command
  SpFN COVID-19 Vaccine

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Protein Subunit

• Tuebingen
  CoVac-1

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Protein Subunit

• SK Bioscience Co Ltd
  NBP2001

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Protein Subunit

• OSE Immunotherapeutics
  CoVepiT

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Protein Subunit

• VaxForm
  CoV2-OGEN1

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 0 countries

  Protein Subunit

• Codagenix Inc
  COVI-VAC

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Live-Attenuated

• The Scientific and Technological Research Council of Turkey
  SARS-CoV-2 VLP Vaccine

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  VLP

• Radboud University
  ABNCoV2

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  VLP

• Providence Health & Services
  CORVax12

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  DNA

• University of Sydney
  COVIGEN

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  DNA

• Symvivo
  bacTRL-Spike

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  DNA

• Stemirna Therapeutics Co Ltd
  mRNACOVID-19 Vaccine

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 0 countries

  RNA

• SENAI CIMATEC
  HDT-301

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 0 countries

  RNA

• Providence Therapeutics Holdings Inc
  PTX-COVID19-B

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  RNA

• GlaxoSmithKline
  CoV2 SAM (LNP)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  RNA

• Moderna
  mRNA-1283

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  RNA

• Moderna
  mRNA-1273.351

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  RNA

• Altimmune Inc
  AdCOVID

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Non Replicating Viral Vector

• Bharat Biotech
  BBV154

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Non Replicating Viral Vector

• NIAID
  SAM-LNP-S

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Non Replicating Viral Vector

• NIAID
  ChAdV68-S

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Non Replicating Viral Vector

• Vaxart
  VXA-CoV2-1

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Non Replicating Viral Vector

• AMMS
  Ad5-nCoV

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Non Replicating Viral Vector

• Tetherex Pharmaceuticals Corporation
  SC-Ad6-1

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Non Replicating Viral Vector

• Universitatsklinikum Hamburg-Eppendorf
  MVA-SARS-2-S

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Non Replicating Viral Vector

• Shenzhen Geno-Immune Medical Institute
  Covid-19/aAPC

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Replicating Viral Vector

• The University of Hong Kong
  DelNS1-nCoV-RBD LAIV

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Replicating Viral Vector

• Meissa Vaccines Inc
  MV-014-212

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Replicating Viral Vector

• City of Hope Medical Center
  COH04S1

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Replicating Viral Vector

• Organization of Defensive Innovation and Research
  FAKHRAVAC (MIVAC)

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Inactivated

• Laboratorio Avi-Mex
  Recombinant NDV Vectored Vaccine

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Inactivated

• Kocak Farma
  Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Inactivated

• The Scientific and Technological Research Council of Turkey
  Adjuvanted Inactivated Vaccine

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Inactivated

5 Vaccines are No Longer Progressing

• Merck Sharp & Dohme Corp
  V591

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 2 trials.

  2 trials in 3 countries

  Replicating Viral Vector

• Imperial
  LNP-nCoVsaRNA

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  RNA

• Institut Pasteur
  COVID-19-101

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 2 countries

  Replicating Viral Vector

• Merck Sharp & Dohme Corp
  V590

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Replicating Viral Vector

• Queensland
  Sclamp

  • Phase 1
  • Phase 2
  • Phase 3
  • Approved

  This vaccine has reached Phase 1 trials.

  1 trial in 1 country

  Protein Subunit